Compare Comfort Systems USA Inc (FIX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Recursion Pharmaceuticals Inc — how do they compare? Comfort Systems USA Inc trades at $1,721.9 (market cap $60.06B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Comfort Systems USA Inc is far larger — about 28.1× Recursion Pharmaceuticals Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FIX | RXRX | |
|---|---|---|
Market Cap | $60.06B | $2.14B |
Volume | 371,896 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $2.07K | $6.79 |
52-Week Low | $790.72 | $2.84 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | $58.53B | $1.66B |
Dividend Yield | 0.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages and support at $1,712. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $12.53 vs. $10.45, while revenue growth accelerates from $9.1B in 2025 to $11.2B in 2026. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
FIX presents a compelling growth opportunity with 55.56% analyst buy ratings and a $2,080 consensus price target offering 19% upside. Key risks include execution challenges in integrating acquisitions and potential margin pressure from rising costs. The stock's premium valuation (P/E 42) requires sustained earnings growth, but strong ROE (55.29%) and expanding data center backlog support the bullish case.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
